Novel Target Discovery
Cancer Immunotherapy
DiscoveryActive
Key Facts
About Noetik
Noetik is a private, pre-clinical stage biotech applying frontier AI and machine learning to oncology. The company has built a large-scale, multimodal tumor data collection and uses it to train foundation models capable of simulating the tumor microenvironment. Its platform aims to address key failures in oncology R&D by improving patient stratification for clinical trials, repositioning existing clinical-stage drugs, and discovering novel therapeutic targets. Backed by leading investors, Noetik is led by a seasoned team with deep expertise in computational biology, AI, drug development, and business strategy from companies like Recursion, Genentech, and Roche.
View full company profileTherapeutic Areas
Other Cancer Immunotherapy Drugs
| Drug | Company | Phase |
|---|---|---|
| CYTER915 | FibroBiologics | Discovery |
| Immuno-Oncology | Resolve Biosciences | Research-Use |
| In vivo CAR-T Program | Deliver Biosciences | Pre-clinical |
| YB328 Microbiome Program | ARC Therapies | Research |
| Engineered Cancer Exosomes (HLA‑G Targeted) | Esco Aster | Preclinical |